BIOM

[Terliso]

BUSINESS SUMMARY  
Biomira, Inc., a biotechnology company, engages in the research and development of therapeutic products for cancer primarily in the United States and Canada. It focuses on the development of synthetic vaccines for active specific immunotherapy. The company's lead product candidates comprise BLP25 Liposome vaccine, a Phase II clinical trial product for the treatment of lung cancer; and Theratope, a Phase III clinical trial carbohydrate vaccine for the treatment of breast cancer. Biomira also develops BGLP40 Liposome Vaccine, a preclinical stage product for various cancer indications. The company has a collaboration agreement with Chiron Corporation for the co-development Theratope vaccine; an agreement with Merck KGaA of Darmstadt for the development, licensing, and co-promotion of L-BLP25 vaccine and Theratope vaccine; and a license and development agreement with Prima BioMed, Ltd for the development and commercialization of a Mannan-MUC1 fusion protein therapeutic vaccine. Biomira was incorporated in 1985 and is based in Edmonton, Canada.



Let's make a quick trade

[traderjbr]

Sweet spot,nice find Terliso!

[setravis]

Outstanding Terliso !
Applaud your work....
Good looking Breakout from the Symmetrical Triangle (continuation) pattern.

AP
Volume Spikes: ABPI SIGA BIOM AMRN VIGN
Thursday October 19, 12:47 pm ET 
Shares of Accentia Biopharmaceuticals Surge on Extraordinary Volume on Drug Study


NEW YORK (AP) -- The following companies were showing unusually heavy volume in trading Thursday on the Nasdaq around noon. Higher-than-normal volume can indicate increased activity by institutions such as mutual funds and insurance companies. Upward stock movement on such volume can show increased confidence among investors, while selling can signal further downward pressure on a stock.


Shares of Accentia Biopharmaceuticals Inc. traded on extraordinarily heavy volume after the Tampa, Fla.-based drug developer said a new study showed its BiovaxID formula sent follicular non-Hodgkins lymphoma following chemotherapy into long-lasting remission in 80 percent of patients.

Nearly 3.1 million shares of Accentia Biopharmaceuticals changed hands by noon, dwarfing the typical daily trading volume of 33,803 shares. The stock rose 47.9 percent to $4.26.

Siga Technologies Inc., a New York-based biotechnology company, said it is selling 2 million shares of its stock for $4.54 per share, or a total of $9 million, and the announcement sent the company's shares into accelerated trading.

By noon, investors exchanged more than 5.6 million Siga shares, almost seven times the average daily trading volume. The stock fell about 6 percent to $4.28.

Shares of Biomira Inc., a Canadian biotechnology researcher, traded with unusually heavy volume. More than 1.7 million of the company's shares had changed hands by noon, compared with daily trading volume of 229,720 shares.

There was no apparent cause for the heightened trading. No analysts released research on the company, and Biomira hasn't issued any news since September.

Amarin Corp., a London-based neuroscience company, said it found buyers for $18.7 million of its shares in a private sale. The company will sell 9 million shares to investors for $2.09 per share, representing a 15 percent discount to Wednesday's closing price.

While in a typical day only 144,738 Amarin shares are traded, the news spurred investors to buy and sell more than 1 million shares by noon. The stock fell 8.5 percent to $2.25.

Shares of Vignette Corp. traded heavily after the Austin, Texas-based Internet applications software maker reported third-quarter profit nearly tripled on higher sales.

Investors bought and sold nearly 1.4 million shares by noon, compared with average daily trading volume of 198,074 shares. The stock rose nearly 8 percent to $15.

[la-onda]

in @ 1.34 $ (cup & handle)
more details @ TTT.net (fous)

[Terliso]

Now, target got hit (Symmetrical Triangle Pattern)

[setravis]

Nice pick Terliso ! Applaud......
This is a great stock to own @ the price you moved in on la-onda.......Applaud
Are you still with it ?

Th Golden Cross is taking place ! (50/200-day MA crossover)

52wk Range: 0.85 - 2.00
Volume: 1,812,342 .................
Avg Vol (3m): 294,853

Technicals
Percentage Gainer

Last Price Quote is:
12.02%above 13-day MA
20.91%above 50-day MA
RS Rating: 90 

Headline News :
Link......  http://finance.yahoo.com/q/h?s=BIOM

[setravis]

AP
Biomira Agrees to Stimuvax Trial Design
Tuesday December 12, 9:48 am ET 
Biomira Agrees With FDA on Late-Stage Clinical Trial Design for Stimuvax Lung Cancer Study


NEW YORK (AP) -- Biotech drug maker Biomira Inc. said Tuesday that it agreed to a particular clinical trial design with the Food and Drug Administration to test Stimuvax for the treatment of advanced lung cancer.


Shares of Biomira rose 13 cents, or 8.9 percent, to $1.59 in early Nasdaq trading.

The company agreed to a Special Protocol Assessment with the agency for the treatment, meaning the agency made suggestions on how the trial should be conducted to increase the chances of approval, and the company agreed to follow the design.

German drug maker Merck KGaA will conduct the clinical trial under a licensing agreement with Biomira.

About 1,300 patients will be enrolled to confirm if Stimuvax allows patients with Stage III non-small cell lung cancer to live longer. Non-small cell lung cancer is the most common form of the disease, accounting for about 75 percent of lung cancers. Stage III lung cancer occurs when the disease has spread beyond the lungs to the lymph nodes.

In a midstage clinical trial, lung cancer patients given Stimuvax survived an average of 30.6 months, compared with the average 13.3 months of those patients given a placebo.

**********************************************



Keeps on a keeping on........

Hey Aussie....stepping up....

52wk Range: 0.85 - 2.00
Volume: 2,840,331....................
Avg Vol (3m): 364,658

Technicals
Most Actives
Percentage Gainer

Last Price Quote is:
12.46%above 13-day MA
21.51%above 50-day MA
RS Rating: 94 

Fundamentals
Key Data:
Market Cap (M): $93.86 

[setravis]

Wanting to move in the Pre-Market

Early now ...Volume @ 28,800 +9.38%

[la-onda]

update:
Biomira "market outperform"

Tuesday, August 28, 2007 1:04:31 PM ET
Rodman & Renshaw

NEW YORK, August 9 (newratings.com) - Analyst Navdeep S Jaikaria of Rodman & Renshaw maintains his "market outperform" rating on Biomira Inc (BIOM.NAS). The target price is set to $3.
In a research note published this morning, the analyst mentions that the entry of PX-478 into clinical development and its potential first-in-class applications in a variety of solid tumours are likely to boost the company's share price. The product has shown encouraging results in pre-clinical studies, with potentially wide applications, the analyst says. Biomira is progressing on track to creating a promising small molecule oncology franchise, Rodman & Renshaw adds.

&

Biomira initiates Phase 1 trial of PX-478 in patients with advanced metastatic cancers
Tuesday , August 28, 2007 08:01ET

EDMONTON, Aug. 28, 2007 (Canada NewsWire via COMTEX) -- Biomira Inc. (Nasdaq: BIOM) (TSX: BRA) today announced that the first patient has been enrolled in a Phase 1 clinical trial of PX-478 in patients with advanced metastatic cancer. PX-478 is a novel small molecule compound designed to inhibit the activity of hypoxia inducible factor (HIF)-1 alpha, a transcription factor that controls the expression of a number of genes important for growth and survival of cancer cells. Genes regulated by HIF-1 alpha contribute to diverse functions such as new blood vessel growth (angiogenesis), use of glucose for energy, and protection against apoptosis (programmed cell death).

"HIF-1 alpha plays a critical role in the response of cancer cells to low oxygen levels, stimulating processes that increase oxygen concentrations and allow tumors to grow and thrive," said Dr. Lynn Kirkpatrick, Ph.D., Chief Scientific Officer of Biomira. "In our preclinical studies, PX-478 produced significant tumor regression and growth delay in a wide variety of models of human cancers, including lung, breast, prostate, colon, kidney, pancreas, and ovarian cancers. We believe this is the first small molecule agent to enter clinical trials that directly lowers levels of HIF-1 alpha protein in tumors."

The Phase 1 trial is expected to enroll up to 36 patients with advanced solid tumors or lymphoma who have failed or are intolerant of standard therapy. PX-478 will be administered orally on days 1 through 5 of a 21-day cycle. Primary objectives of the study include establishment of a maximum tolerated dose, evaluation of safety, and analyses of pharmacodynamic and pharmacokinetic profiles of PX-478. Other objectives are to evaluate the effects of PX-478 on tumor blood flow and vascular permeability as measured by DCE-MRI, and to evaluate the anti-tumor activity of PX-478 in patients with advanced malignancies.

"We are very excited about the potential for PX-478 as an anti-cancer compound with broad potential application," said Dr. Robert L. Kirkman, MD, President and Chief Executive Officer of Biomira. "We are also pleased with the progress of our pipeline, as demonstrated by the initiation of this trial on schedule. This is our second small molecule compound to enter clinical development, and we expect to file an investigational new drug (IND) application for PX-866, a third small molecule, by the end of 2007. Together with PX-12, currently in Phase 2 development, the advancement of these compounds reflects our significant progress in creating value from our acquisition of ProlX Pharmaceuticals less than one year ago."

&

Stimuvax(R) Phase II data highlight three-year survival results for patients with non-small cell lung cancer
Wednesday, September 05, 2007 08:05ET

EDMONTON, Sep. 5, 2007 (Canada NewsWire via COMTEX) -- Biomira Inc. (Nasdaq: BIOM) (TSX: BRA) today announced the presentation of three-year survival results from a randomized Phase II trial of the Stimuvax(R) MUC-1 vaccine in non-small cell lung cancer (NSCLC). The results suggest that Stimuvax combined with best supportive care (BSC) may provide survival benefits to patients with unresectable stage IIIB NSCLC who had either responded or had stable disease after initial radio-chemotherapy, compared with patients receiving BSC alone. Dr. Charles Butts, from the Department of Medical Oncology, Cross Cancer Institute, Edmonton, Alberta and lead investigator of the Phase II study presented the data yesterday (Abstract No. B1-01) at the International Association for the Study of Lung Cancer (IASLC) Congress in Seoul, South Korea.

The updated survival results show that approximately twice as many patients were still alive at three years in the Stimuvax arm compared with BSC alone (49% (n=17) vs. 27% (n=8)), representing a 45% reduction in mortality. As previously reported, patients with stage IIIB locoregional disease who received Stimuvax in this trial also experienced a 17.3 month difference in median survival compared with patients receiving BSC alone (30.6 months vs. 13.3 months, respectively). Patients receiving Stimuvax in this trial also reported mild to moderate side effects limited to flu-like symptoms, gastro-intestinal disturbances and mild injection site reactions.

"The updated survival data are encouraging and support the need for further investigation via the ongoing Phase III trial of Stimuvax as a maintenance therapy for patients with advanced lung cancer," commented Dr. Butts.

Based on the Phase II results, Stimuvax has entered its Phase III development and the START (Stimulating Targeted Antigenic Responses to NSCLC) trial is currently open for enrollment. The START trial is being conducted by Merck KGaA of Darmstadt, Germany, which has licensed worldwide development and commercialization rights to Stimuvax from Biomira. Stimuvax is being developed in Europe by Merck KGaA and in the United States by its affiliate, EMD Serono Inc.

"Patients with unresectable stage III non-small cell lung cancer have significant unmet medical need, and the START study is the first Phase III program to evaluate a therapeutic cancer vaccine in this population," said Dr. Robert L. Kirkman, MD, President and Chief Executive Officer of Biomira. "If these survival results are statistically confirmed in the Phase III trial, Stimuvax has the potential to become an important tool in the treatment of lung cancer."

According to the American Cancer Society, lung cancer is the leading cause of cancer-related deaths in both men and women worldwide, with approximately 80% of cases classified as NSCLC. Current survival rates for NSCLC are low, with only 16% of patients alive five years post-diagnosis. Unfortunately for most patients, current treatments provide limited success. Stimuvax is an innovative cancer vaccine designed to stimulate the body's immune system to identify and destroy cancer cells expressing MUC1, a protein antigen that is widely expressed on common cancers including lung, breast and colorectal.

&

Biomira Announces Plan to Reincorporate in the United States
Wednesday, September 12, 2007 09:04ET

EDMONTON, BELLEVUE, WASHINGTON, Sept. 12 /PRNewswire-FirstCall/ - Biomira Inc. (Nasdaq: BIOM) (TSX: BRA) (the "Company") today announced that the Company's Board of Directors has approved a proposal to change its jurisdiction of incorporation from the federal jurisdiction of Canada to the State of Delaware in the United States of America through a plan of arrangement. Under the plan of arrangement, which is subject to shareholder and court approval, Biomira will migrate to the United States by creating a holding corporation based in the State of Delaware, Biomira Corporation, which will be the ultimate parent corporation of a successor corporation of the current Biomira and its subsidiaries. Biomira Corporation intends to establish its headquarters in or near Seattle, Washington.

"We believe that reincorporation in Delaware is the right strategic move to increase long-term shareholder value," said Robert L. Kirkman, M.D., President and Chief Executive Officer of Biomira. "This move is intended to raise our profile in the U.S. financial markets, with the goals of increasing the visibility of our exciting product pipeline among U.S. institutional investors and providing access to a larger pool of investment capital. Additionally, we believe that relocating to a major biotechnology center such as Seattle will provide greater opportunity to attract and retain key personnel."

Upon the completion of the proposed arrangement, holders of common shares of Biomira Inc. will receive one-sixth of a share of common stock of Biomira Corporation in exchange for each common share of Biomira Inc., which will have the effect of a 6 for 1 reverse stock split of Biomira Inc. common shares.

"We believe that this effective reverse stock split should result in a higher trading price for the shares of Biomira Corporation and ultimately result in increased shareholder value," continued Dr. Kirkman. "A higher share price may allow investment in Biomira Corporation by institutional investors whose policies preclude investing in stock with lower share prices. Many brokerage firms prohibit using lower priced stocks in margin accounts. A higher price also is expected to benefit shareholders by reducing the risk of a NASDAQ Global Market delisting proceeding based on the minimum $1 share price rule."

"The relocation of our headquarters to the Seattle area is not expected to result in a significant change in our operations in Edmonton, Alberta," continued Dr. Kirkman. "We have a highly skilled, productive and dedicated workforce in Edmonton that we intend to maintain. However, a significant portion of our operations, particularly related to our small molecule development programs, is already in the U.S., and we believe that our Seattle area location will help us to attract the additional staff we need to advance these programs as rapidly and successfully as possible."

The transaction will be completed through a plan of arrangement, which will require the approval of two-thirds of the common and preference shares represented at a special meeting of Biomira's shareholders, voting as a class. Such a meeting is expected to take place in Edmonton, Alberta following the distribution of a definitive proxy statement/prospectus contained as part of a registration statement filed with the United States Securities and Exchange Commission (the "SEC") and receipt of an interim order with respect to the proposed plan of arrangement from the Alberta Court of Queen's Bench. Biomira Corporation today filed a registration statement on Form S-4 with the SEC that includes a preliminary proxy statement/prospectus covering the proposed plan of arrangement and the shares to be issued to Biomira's shareholders in the plan of arrangement. Assuming that the SEC declares the registration statement effective, the shareholders approve of the plan of arrangement, and the Alberta Court of Queen's Bench issues a final order approving the plan of arrangement, Biomira currently estimates that the transactions contemplated by the plan of arrangement should be completed in early 2008.

chart:

[setravis]

Two thundering days, may have hit the bottom.......


52wk Range: 0.34 - 1.70
Volume: 2,770,325
Avg Vol (3m): 379,042

[setravis]

 Biomira Shareholders Approve Move to U.S.
PR Newswire (Tue, Dec 4) 



Press Release Source: Biomira Inc.


Court issues final order approving Biomira's move to U.S. and name change to Oncothyreon
Wednesday December 5, 12:52 pm ET


EDMONTON, Dec. 5 /PRNewswire-FirstCall/ - Biomira Inc. (Nasdaq: BIOM - News; TSX: BRA - News; "Biomira", the "Company") announced that the Alberta Court of Queen's Bench today issued a Final Order approving the plan of arrangement under which the Company will move to the United States and change its name to Oncothyreon Inc. ("Oncothyreon"). Biomira also announced that the Board of Directors, upon review of the shareholder vote and other pertinent matters, yesterday voted unanimously to proceed with the plan of arrangement.


Biomira intends to file articles of amendment to effect the plan of arrangement on or about December 10, 2007, and to commence trading as Oncothyreon on the Nasdaq National Market under the symbol "ONTY" and on the Toronto Stock Exchange under the symbol "ONY" shortly thereafter. Letters of transmittal are expected to be mailed to registered shareholders commencing later today.

Upon completion of the plan of arrangement, Oncothyreon will become the parent corporation of a successor corporation of the current Biomira and its subsidiaries. Holders of common shares of Biomira will receive one-sixth of a share of common stock of Oncothyreon in exchange for each common share of Biomira. Oncothyreon intends to establish its headquarters in or near Seattle, Washington.

About Biomira

Biomira is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Biomira's goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients.

Forward Looking Statements

In order to provide Biomira's investors with an understanding of its current intentions and future prospects, this release contains statements that are forward looking, including statements relating to the proposed reincorporation of Biomira from Canada to the United States and the timing thereof. These forward-looking statements represent Biomira's intentions, plans, expectations and beliefs and are based on its management's experience and assessment of historical and future trends and the application of key assumptions relating to future events and circumstances.

Forward-looking statements involve risks and uncertainties, including risks and uncertainties related to the proposed reincorporation transaction, Biomira's business and the general economic environment. Many of these risks and uncertainties are beyond Biomira's control. These risks, uncertainties and other factors could cause our actual results to differ materially from those projected in forward-looking statements. Risks, uncertainties, and assumptions include those predicting the completion of the proposed arrangement and reincorporation and the other risks and uncertainties described in the reports and other documents, including the registration statement on Form S-4, filed by either Biomira Inc. or Oncothyreon Inc. with the SEC and/or Canadian regulatory authorities.

Although Biomira believes that any forward-looking statements contained herein are reasonable, it can give no assurance that its expectations are correct. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. For a detailed description of the risks and uncertainties associated with Biomira and Oncothyreon, you are encouraged to review the official corporate documents filed with the securities regulators in Canada and the United States, including the risk factors described in the amended registration statement on Form S-4 filed by Oncothyreon Inc. with the SEC and on SEDAR. Biomira and Oncothyreon are under no obligation to (and expressly disclaim any such obligation to) update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.
--------------------------------------------------------------------------------
Source: Biomira Inc.